Aravive, Inc. Common Stock
ARAV
ARAV: Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
moreShow ARAV Financials
Recent trades of ARAV by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Bob Gibbs House / R | Sale $158.65 | Dec. 28, 2018 |
Recently reported changes by institutional investors
Quarterly net insider trading by ARAV's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on ARAV's company Twitter account
Number of mentions of ARAV in WallStreetBets Daily Discussion
Recent insights relating to ARAV
Recent picks made for ARAV stock on CNBC
ETFs with the largest estimated holdings in ARAV
Flights by private jets registered to ARAV